Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

弘和仁愛
HOSPITAL CORPORATION

Hospital Corporation of China Limited
弘和仁愛醫療集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3869)

ANNOUNCEMENT ON CHANGE OF DIRECTORS AND NON-COMPLIANCE WITH RULES 3.10(1), 3.10A, 3.21 AND 3.27A OF THE LISTING RULES

RESIGNATION OF DIRECTORS

The board ("**Board**") of directors ("**Directors**", and each individually a "**Director**") of Hospital Corporation of China Limited (the "**Company**", together with its subsidiaries collectively, the "**Group**") hereby announces that Mr. CHEN Shuai (陳帥先生) ("**Mr. Chen**") has resigned as an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Authorised Representative**"), acting chief executive officer of the Company, chairman of the nomination committee of the Board ("**Nomination Committee**"), chairman of the Board and executive Director with effect from 22 June 2026 due to work arrangements. Mr. SHI Luwen (史錄文先生) ("**Mr. Shi**") has resigned as a member of the Nomination Committee, member of the audit committee of the Board ("**Audit Committee**") and independent non-executive Director with effect from 22 June 2026 due to work arrangements.

Each of Mr. Chen and Mr. Shi has confirmed that he did not have any disagreements with the Board, nor any other matters related to his resignation are required to be brought to the attention of the shareholders of the Company.

The Board would like to express its gratitude to Mr. Chen and Mr. Shi for their contributions to the Group.

NON-COMPLIANCE WITH RULES 3.10(1), 3.10A, 3.21 AND 3.27A OF THE LISTING RULES

Following the resignation of Mr. Shi, the number of independent non-executive Directors on the Board is now less than three as required under Rule 3.10(1) of the Listing Rules and also represents less than one-third of the members of the Board as required under Rules 3.10A of the Listing Rules.

According to Rule 3.21 of the Listing Rules, the Audit Committee shall comprise a minimum of three members. Following the resignation of Mr. Shi, the number of members of the Audit Committee would decrease from three to two, below the minimum number as required under Rule 3.21 of the Listing Rules.

According to Rule 3.27A of the Listing Rules, the Nomination Committee shall comprise a majority of independent non-executive Directors. Following the resignation of Mr. Shi, the members of the Nomination Committee would fall below a majority of independent non-executive Directors as required under Rule 3.27A of the Listing Rules.

The Company is endeavoring to identify a suitable candidate to act as an additional member of the Board, the Audit Committee and the Nomination Committee to meet the requirement set out in Rule 3.10(1), 3.10A, 3.21 and 3.27A of the Listing Rules as soon as practicable, and in any event within three months as required under Rules 3.11, 3.23 and 3.27C of the Listing Rules, and will make necessary announcement(s) as and when appropriate.

APPOINTMENT OF DIRECTORS

The Board hereby announces that pursuant to the articles of association ("**Articles of Association**") of the Company and upon recommendation made by the Nomination Committee, with effect from 22 June 2026, (i) Mr. CAO Yonggang（曹永剛先生）("**Mr. Cao**") has been appointed as a non-executive Director, chairman of the Board and chairman of the Nomination Committee; and (ii) Mr. LANG Xiaofeng（郎曉峰先生）("**Mr. Lang**") has been appointed as an executive Director, the Authorised Representative and chief executive officer of the Company.

Mr. Cao, aged 54, joined Hony Capital (a series of private equity investment funds, together with their respective management companies/general partners, "**Hony Capital**") in 2004 and currently serves as group chief executive officer of Hony Capital. He plays a critical role in the firm's investment decisions and daily operations from the perspectives of corporate development, risk management and governance. He oversees the firm's full spectrum of investment strategies, including PE, public funds, hedge funds, RE funds and VC funds, with total assets under management exceeding RMB120 billion.

With extensive legal background and professional experience, Mr. Cao has participated in many important investments of Hony Group, including projects such as CSPC Pharmaceutical Group, Simcere Pharmaceutical, Linyang Solar Energy and Boloni Home. He also previously served as chairman of the supervisory committee of Zoomlion Heavy Industry Science & Technology Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code: 000157 and the Stock Exchange with stock code: 01157) and a member of the supervisory committee of Happy Go (now Mango Super Media Co., Ltd., a company listed on the Shenzhen Stock Exchange with stock code: 300413). Since 22 May 2026, Mr. Cao has been appointed as a non-executive director of YNBY International Limited (a company listed on the Stock Exchange with stock code: 00030).

Mr. Cao holds an LL.B. in Civil and Commercial Law from Nankai University, an LL.M. in International Law from Peking University, an LL.M. in International Law and WTO Law from Erasmus University Rotterdam, and an EMBA degree from China Europe International Business School (CEIBS).

The term of office of Mr. Cao shall be three years commencing on 22 June 2026, and is subject to retirement by rotation and re-election in accordance with the Articles of Association. The Company will enter into a service contract with Mr. Cao. Mr. Cao will not receive any emoluments pursuant to the service contract.

As at the date of this announcement, so far as the Directors are aware and save as disclosed above, Mr. Cao (i) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas during the past three years; and (ii) does not hold any other position in the Group.

Mr. Lang (formerly known as Uyunbilig (烏雲畢力格)), aged 43, joined Hony Capital in 2014 and currently serves as a managing director of Hony Capital responsible for health industry, where he was previously responsible for various investment and management functions and held positions including senior investment manager and senior business assistant to the chief executive officer. Mr. Lang served as the assistant to the chairman and the chief company development officer of the Company from September 2020 to September 2021. Mr. Lang also serves as a supervisor of Honghe Pharmaceutical (Zhejiang) Co., Ltd. (弘和醫藥(浙江)有限公司), a subsidiary of the Company.

From January 2009 to December 2014, Mr. Lang served as a business manager at China Railway Construction Investment Company. Mr. Lang obtained a master's degree in Commerce and Information Technology from the University of Melbourne in 2007 and a bachelor's degree in Information and Information Management from Dalian University of Technology in 2005.

The term of office of Mr. Lang shall be three years commencing on 22 June 2026, and is subject to retirement by rotation and re-election in accordance with the Articles of Association. The Company will enter into a service contract with Mr. Lang. Mr. Lang will not receive any emoluments as a Director pursuant to the service contract. Mr. Lang is entitled to an annual salary of HKD1 million as the chief executive officer of the Company. Such arrangement was determined by the Board with reference to his experience, duties and scope of responsibilities, the Company's remuneration policy and the prevailing market rate, and is subject to review by the remuneration committee of the Company ("**Remuneration Committee**") from time to time. Also, Mr. Lang may receive a discretionary bonus and other benefits in kind, subject to the recommendation of the Remuneration Committee and approval of the Board.

As at the date of this announcement, so far as the Directors are aware and save as disclosed above, Mr. Lang (i) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas during the past three years; and (ii) does not hold any other position in the Group.

Save as disclosed above, each of Mr. Cao and Mr. Lang (i) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company, (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong), and (iii) does not hold other major appointments and professional qualifications.

Save as disclosed above, there are no other matters that need to be disclosed pursuant to the requirements under Rule 13.51(2) of the Listing Rules, nor is there any other matter relating to the appointments of Mr. Cao and Mr. Lang that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to the appointments of Mr. Cao and Mr. Lang.

By Order of the Board
Hospital Corporation of China Limited
CAO Yonggang
Chairman

Hong Kong, 22 June 2026

As at the date of this announcement, the Directors of the Company are Mr. LANG Xiaofeng, Mr. PU Chengchuan and Ms. PAN Jianli being the executive Directors; Mr. CAO Yonggang, Ms. LIU Lu and Ms. WANG Nan being the non-executive Directors; Mr. DANG Jinxue and Mr. ZHOU Xiangliang being the independent non-executive Directors.